Barclays lowered the firm’s price target on Thermo Fisher (TMO) to $625 from $650 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Private Markets: Nuclear, hypersonics score nearly $800M in fresh capital
- Thermo Fisher announces collaboration with Precision Health Research
- Citi adds ‘upside 90-day catalyst watch’ on Thermo Fisher
- Thermo Fisher price target lowered, added to ‘Tactical Outperform’ at Evercore
- Citi, Meta among ‘Top 10 US Ideas for Q2’ at BofA